{"id":"W2160137787","doi":"10.1093/neuonc/nop015","title":"A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy","year":2009,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Cancer Institute","keywords":"Erlotinib; Medicine; Rash; Glioma; Internal medicine; Epidermal growth factor receptor; Oncology; Anaplastic astrocytoma; Erlotinib Hydrochloride; Gastroenterology; Cancer research; Cancer; Astrocytoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009050587,0.0001844545,0.0004708212,0.000248536,0.00004647257,0.000006309491,0.00004630774,0.0001143796,0.00001504315],"category_scores_gemma":[0.00006527139,0.0001271162,0.00005631633,0.000248116,0.00006763503,0.00006623738,0.0000155681,0.0001270802,0.000001575545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000959177,"about_ca_system_score_gemma":0.0001142062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001237172,"about_ca_topic_score_gemma":0.00003056592,"domain_scores_codex":[0.9987499,0.00009152389,0.0003827339,0.0003098984,0.0002217352,0.0002442765],"domain_scores_gemma":[0.9992055,0.0001146326,0.0002735401,0.0001729837,0.0001087856,0.0001245685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2127576,0.04553742,0.03303514,0.00001622891,0.00008104683,0.0005656628,0.001123206,0.000002573369,0.03378293,0.00005050673,0.0001211037,0.6729266],"study_design_scores_gemma":[0.4568392,0.3447,0.1712441,0.00008931787,0.00009248695,0.00004169205,0.00004062246,0.00008662569,0.02502038,0.00002158473,0.001686454,0.0001374998],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960856,0.0001886208,6.622047e-7,0.001292855,0.0001721634,0.002137392,0.00002354643,0.00001970368,0.00007939069],"genre_scores_gemma":[0.9992595,0.0001099489,0.0001332529,0.0002908719,0.00006008495,0.00009696696,0.00003519881,0.00001344989,6.83246e-7],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6727891,"threshold_uncertainty_score":0.5183648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01601057918713706,"score_gpt":0.3083108920151955,"score_spread":0.2923003128280585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}